Class IITerminatedD-0159-2020
Drug recall · November 6, 2019
Lyophilized Sermorelin w/ GHRP2 3 mg For injection recall
Why: Lack of Sterility Assurance.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Lyophilized Sermorelin w/ GHRP2 3 mg For injection, Rx Only, Compounded by: Innoveix Addison, TX 75001 800-370-1910
- Lots / codes
Lots: SER 925 Exp. 11/4/19; SER 930 Exp. 11/18/19; SER 935 Exp. 2/21/20; SER 400 Exp. 4/1/20; SER 405 Exp. 5/11/20; SER 410 Exp. 7/15/20
- Quantity
- 1747 vials
- Company
- Innoveix Pharmaceuticals Inc, Addison, TX
- Distribution
- Nationwide within the United States
- Initiated
- October 10, 2019 · Voluntary: Firm initiated
- Classified
- October 28, 2019
- Reported
- November 6, 2019
- Ended
- January 14, 2022
- How notified
- Press Release
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Class IITerminatedNov 6, 2019Lyophilized Chorionic Gonadotropin 11Innoveix Pharmaceuticals Inc · D-0157-2020Class IITerminatedNov 6, 2019Lyophilized Human Chorionic Gonadotropin 5Innoveix Pharmaceuticals Inc · D-0158-2020Class IITerminatedNov 6, 2019Lyophilized Human Chorionic Gonadotropin 5Innoveix Pharmaceuticals Inc · D-0160-2020
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.